TARGETED INSERTION INTO MAMMALIAN SEQUENCES, ENHANCING GENE EXPRESSION Russian patent published in 2024 - IPC C07K14/05 C12N5/07 C12N9/22 C12N15/10 C12N15/90 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, in particular to an engineered cell line of mammalian cells for expression of a therapeutic protein, containing in the cell genome at least one locus containing an insertion site of an endogenous retrovirus (ERV) sequence, wherein said at least one locus contains: (i) a) sequence ERV C 109F, or b) an insertion site and, optionally, sequence fragments a), and/or (ii) an equivalent allelic sequence of a wild type (i), and at least one transgene coding at least one transgene expression product inserted into at least one transgene expression product one locus. Also disclosed is a population of cells for expression of a therapeutic protein, a method of incorporating a transgene into the genome of a mammalian cell line. Invention also relates to a kit for introducing at least one transgene into a cell. Advantage of the present invention is the possibility of achieving a high level and / or stable production of the transgene expression product(s). Incorporation and expression of the transgene can be facilitated by modulating the DNA repair pathways of the cell, for example, by transient expression of a gene coding a protein which is part of the DNA repair pathway during insertion of the transgene.

EFFECT: disclosed is targeted insertion into mammalian sequences, which enhances gene expression.

23 cl, 16 dwg, 4 tbl, 3 ex